Lilly Sets $50 US Medicare Price for Zepbound as Canada Awaits
Eli Lilly announced that US Medicare beneficiaries will pay no more than $50 monthly for Zepbound starting April 1, 2026, as Canadian patients continue waiting for public coverage decisions.
US Medicare Agreement Details
The pharmaceutical company reached an agreement with the US government to cap monthly costs for Mounjaro (tirzepatide) at $50 for Medicare beneficiaries. The pricing applies to multi-dose pen formulations and represents a significant reduction from current market rates.
This pricing structure comes as Lilly faces increasing pressure from generic competition expected to enter markets worldwide following patent expirations.
Canadian Coverage Landscape
In Canada, tirzepatide remains under review by the Canadian Drug Agency for potential public plan coverage. The agency's evaluation process continues as provinces and territories await guidance on formulary inclusion decisions.
Current Canadian pricing for tirzepatide products varies significantly across pharmacies, with monthly costs typically ranging from $300 to $570 depending on dosage strength and retailer. Major chains including Shoppers Drug Mart, Costco, and Walmart report different pricing structures.
Market Context
The US Medicare pricing announcement follows Lilly's December 2025 decision to reduce Canadian prices for both Mounjaro and Zepbound by 20% or more. These reductions took effect December 29, 2025, as the company prepared for generic competition.
Health Canada currently reviews nine generic semaglutide applications, with some submissions dating back to February 2024. The regulatory body maintains a 180-day standard review timeline for generic drug applications.
Provincial Considerations
Canadian provinces monitor US pricing developments as they evaluate potential coverage frameworks for GLP-1 medications. Public drug plans across Ontario, British Columbia, Alberta, and Quebec continue assessing cost-effectiveness and budget impact projections.
Private insurance coverage varies significantly, with some employer plans covering tirzepatide products while others await generic alternatives. Patients can check current coverage status through our insurance coverage checker.
Generic Timeline
Generic semaglutide manufacturers including Apotex, Sandoz, and Teva continue working toward Health Canada approval. Industry analysts expect first generic approvals could arrive as early as summer 2026, potentially reducing monthly costs by 65% or more.
For current pricing information and updates on generic availability, patients can access our generic semaglutide tracker and comprehensive FAQ section.
This article is for informational purposes only and does not constitute medical advice.
Get notified when generic prices go live
We’ll send one email the moment generic semaglutide prices are listed at Canadian pharmacies. No spam.
Get notified when generic semaglutide becomes available in Canada
Expected Q3 2026 — be the first to know
